Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazbentetol (SPG302) in mild-to-moderate Alzheimer's disease
NCT06427668Phase 2Active, not recruiting
- Sponsor
- Spinogenix
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tazbentetol in Alzheimer's disease (AD), sponsored by Spinogenix. Started Jul 2024; status: active, not recruiting.
02
Drugs
tazbentetol
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06427668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06427668.